{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-22-000057","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.499941+00:00","generated_at":"2026-06-25T22:09:24.269532+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Exelixis Q1 2022 revenue $356M, EPS $0.21; cabozantinib franchise $310.3M","bullets":["Total revenues $356.0M vs $270.2M YoY; net product revenues $310.3M vs $227.2M, driven by higher cabozantinib volume.","GAAP net income $68.6M ($0.21 diluted EPS) vs $1.6M ($0.00); non-GAAP EPS $0.26 vs $0.09.","Cabozantinib franchise growth: increased demand for CABOMETYX+OPDIVO in first-line RCC and DTC label expansion.","Cash and investments $2.0B at March 31, 2022, up from $1.9B at December 31, 2021.","Pipeline advancing: XL092 phase 3 STELLAR-303 to initiate Q2 2022; phase 1 trials of XL092, XB002, XL102 ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-22-000057","json":"https://secwatch.observer/filing/0000939767-22-000057.json","markdown":"https://secwatch.observer/filing/0000939767-22-000057.md","text":"https://secwatch.observer/filing/0000939767-22-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000057/0000939767-22-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976722000057/exel-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:09:24.269532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}